benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
Company profile
Ticker
BNTC
Exchange
Website
CEO
Gregory West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Benitec Biopharma Proprietary Limited • Benitec Australia Proprietary Limited • Benitec Limited • Benitec, Inc. • RNAi Therapeutics, Inc. • Tacere Therapeutics, Inc. • Benitec, LLC • Benitec IP Holdings, Inc. ...
BNTC stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
8 Mar 24
EFFECT
Notice of effectiveness
6 Mar 24
S-3
Shelf registration
23 Feb 24
8-K
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
13 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
S-8
Registration of securities for employees
22 Dec 23
8-K
Departure of Directors or Certain Officers
7 Dec 23
8-K
Benitec Biopharma Announces First Subject Dosed in Phase
30 Nov 23
8-K
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
13 Nov 23
10-Q
2024 Q1
Quarterly report
13 Nov 23
Transcripts
Latest ownership filings
4
Jerel A. Banks
8 Mar 24
4
Megan Boston
8 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
SC 13G/A
FRANKLIN RESOURCES INC
11 Dec 23
4
Edward F Smith
7 Dec 23
4
Peter Francis
7 Dec 23
4
J KEVIN BUCHI
7 Dec 23
SC 13G/A
FRANKLIN RESOURCES INC
11 Sep 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.96 mm | 1.70 mm | 1.53 mm | 1.55 mm |
Cash used (since last report) | n/a | n/a | 11.72 mm | 10.16 mm | 9.13 mm | 9.25 mm |
Cash remaining | n/a | n/a | 14.16 mm | 15.71 mm | 16.74 mm | 16.63 mm |
Runway (months of cash) | n/a | n/a | 7.2 | 9.3 | 11.0 | 10.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 1 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.56 bn |
Total shares | 14.09 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BEN Franklin Resources | 10.00 mm | $2.39 bn |
CVI Investments | 1.47 mm | $0.00 |
Oliveira Steven Michael | 1.00 mm | $440.00 k |
Suvretta Capital Management | 769.00 k | $3.12 bn |
Lincoln Park Capital Fund | 423.53 k | $0.00 |
Alpha Capital Anstalt | 124.66 k | $327.00 k |
Vanguard | 74.77 k | $17.83 mm |
VIRT Virtu Financial | 52.87 k | $13.00 k |
Geode Capital Management | 48.22 k | $11.50 mm |
MS Morgan Stanley | 38.60 k | $9.21 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Jerel A. Banks | Options Common Stock | Grant | Acquire A | No | No | 5.21 | 466,554 | 2.43 mm | 466,554 |
6 Mar 24 | Megan Boston | Options Common Stock | Grant | Acquire A | No | No | 5.21 | 200,004 | 1.04 mm | 200,004 |
6 Dec 23 | Buchi J Kevin | Options Common Stock | Grant | Acquire A | No | No | 3.1301 | 35,000 | 109.55 k | 35,000 |
6 Dec 23 | Smith Edward F | Options Common Stock | Grant | Acquire A | No | No | 3.1301 | 35,000 | 109.55 k | 35,000 |
6 Dec 23 | Peter Francis | Options Common Stock | Grant | Acquire A | No | No | 3.1301 | 35,000 | 109.55 k | 35,000 |
News
12 Health Care Stocks Moving In Monday's Intraday Session
4 Mar 24
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $10
15 Feb 24
Benitec Biopharma Q2 EPS $(2.64) Up From $(3.34) YoY
13 Feb 24
JMP Securities Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $8
24 Jan 24